Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
Are there other investigations you would pursue to guide decision?
Related Questions
How do you approach management for CCUS with severe cytopenias?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
What adverse events would make you switch off nivo + AVD therapy and to what second line therapy in patients with Hodgkin Lymphoma?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How do you approach frontline treatment for an elderly patient with adult T-cell leukemia-lymphoma (ATL)?